| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050122441 |
| P356 | DOI | 10.1038/NRRHEUM.2013.168 |
| P698 | PubMed publication ID | 24217582 |
| P50 | author | Gerd-Rüdiger Burmester | Q47261275 |
| P2093 | author name string | Thomas Dörner | |
| Eugen Feist | |||
| P2860 | cites work | TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 |
| Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis | Q22299388 | ||
| The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens | Q70328576 | ||
| A reexamination of the relationship between active rheumatoid arthritis and the acquired immunodeficiency syndrome | Q71561261 | ||
| CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity | Q71755859 | ||
| Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies | Q72103388 | ||
| Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls | Q80730949 | ||
| IL-21 regulates Th17 cells in rheumatoid arthritis | Q82538769 | ||
| The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial | Q83223892 | ||
| Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III | Q83571290 | ||
| Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort | Q83988231 | ||
| Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study | Q84310525 | ||
| The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus | Q84579960 | ||
| Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study | Q86014195 | ||
| Pulmonary alveolar proteinosis | Q87355329 | ||
| Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis | Q94699138 | ||
| The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation | Q24322589 | ||
| The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells | Q24803832 | ||
| Tregitope update: mechanism of action parallels IVIg | Q26853072 | ||
| Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling | Q27314385 | ||
| Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis | Q27691388 | ||
| BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases | Q28205999 | ||
| Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss | Q28245637 | ||
| Interleukin-17 and type 17 helper T cells | Q28256510 | ||
| The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy | Q28260108 | ||
| Tumor regression in cancer patients by very low doses of a T cell-engaging antibody | Q28290910 | ||
| Cytokines in the pathogenesis of rheumatoid arthritis | Q28303865 | ||
| Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study | Q28660706 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies | Q30500362 | ||
| Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis | Q33508917 | ||
| Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. | Q33684899 | ||
| Ten years with biologics: to whom do data on effectiveness and safety apply? | Q33749195 | ||
| Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment | Q34093086 | ||
| LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study | Q34096856 | ||
| Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome | Q34108411 | ||
| Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 | ||
| Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study | Q34187345 | ||
| Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial | Q34275637 | ||
| Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis | Q34317197 | ||
| JAKs and STATs in immunity, immunodeficiency, and cancer | Q34321767 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. | Q34533631 | ||
| Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood | Q34566056 | ||
| IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. | Q34583514 | ||
| Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. | Q34613920 | ||
| Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases | Q34615216 | ||
| Immunity to citrullinated proteins in rheumatoid arthritis | Q34732863 | ||
| Th17 and natural Treg cell population dynamics in systemic lupus erythematosus | Q34978528 | ||
| The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets | Q35111838 | ||
| Expression of cell surface markers after human B lymphocyte activation | Q35386633 | ||
| Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial | Q35540009 | ||
| Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial | Q36094059 | ||
| CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction | Q36287462 | ||
| Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice. | Q36390894 | ||
| Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy | Q36571741 | ||
| Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. | Q36672726 | ||
| Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition | Q36694143 | ||
| Mechanisms of killing by anti-CD20 monoclonal antibodies. | Q36927853 | ||
| CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. | Q36978507 | ||
| The central role of T cells in rheumatoid arthritis | Q36988984 | ||
| Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 | ||
| Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes | Q37073761 | ||
| Antibodies to citrullinated proteins in arthritis: pathology and promise | Q37128331 | ||
| Colony-stimulating factors in inflammation and autoimmunity. | Q37190439 | ||
| An overview of IL-17 function and signaling | Q37243055 | ||
| Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept | Q37249170 | ||
| Is there a feudal hierarchy amongst regulatory immune cells? More than just Tregs | Q37350865 | ||
| A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview | Q37428436 | ||
| Plasticity of CD4(+) FoxP3(+) T cells | Q37509592 | ||
| B-cell-directed therapies for autoimmune disease | Q37542901 | ||
| Regulatory T cells as therapeutic targets in rheumatoid arthritis | Q37607071 | ||
| Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers | Q37680404 | ||
| Rheumatoid arthritis progression mediated by activated synovial fibroblasts | Q37782498 | ||
| Regulatory B cells in autoimmunity: developments and controversies. | Q37790605 | ||
| Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis | Q37811639 | ||
| Therapeutic potential of Tregs to treat rheumatoid arthritis | Q37924394 | ||
| Inflammatory bone loss: pathogenesis and therapeutic intervention | Q37989394 | ||
| MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy | Q38001790 | ||
| Autoimmune arthritis: the interface between the immune system and joints | Q38011356 | ||
| B-cell depletion in the treatment of lupus nephritis | Q38026784 | ||
| Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity | Q38071110 | ||
| Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis | Q38078921 | ||
| Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective | Q38344731 | ||
| Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. | Q40474288 | ||
| Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors | Q40532147 | ||
| Secretion of gelatinases and activation of gelatinase A (MMP-2) by human rheumatoid synovial fibroblasts | Q40765877 | ||
| A multitude of kinases--which are the best targets in treating rheumatoid arthritis? | Q40840109 | ||
| CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study | Q40949199 | ||
| Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus | Q42518281 | ||
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
| Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy | Q42971266 | ||
| Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis | Q43048001 | ||
| CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation | Q43406136 | ||
| Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial | Q43696394 | ||
| CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation | Q44173489 | ||
| Characterization of a human B lymphocyte-specific antigen. | Q44191670 | ||
| Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study | Q44755697 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia | Q46280969 | ||
| The pathogenesis of rheumatoid arthritis: new insights from old clinical data? | Q48029200 | ||
| Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. | Q54292098 | ||
| Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. | Q54584374 | ||
| CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis | Q56902845 | ||
| Increased Interleukin 21 (IL-21) and IL-23 Are Associated with Increased Disease Activity and with Radiographic Status in Patients with Early Rheumatoid Arthritis | Q56974064 | ||
| Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome | Q57212191 | ||
| Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents | Q57271792 | ||
| Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis | Q57350588 | ||
| Pulmonary Alveolar Proteinosis | Q57749775 | ||
| Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis | Q58466080 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 77-88 | |
| P577 | publication date | 2013-11-12 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Emerging cell and cytokine targets in rheumatoid arthritis | |
| P478 | volume | 10 |
| Q90446908 | Accelerated immunosenescence in rheumatoid arthritis: impact on clinical progression |
| Q42763577 | Adipose-derived mesenchymal stromal cells modulate experimental autoimmune arthritis by inducing an early regulatory innate cell signature. |
| Q38431512 | Advances in use of immunomodulatory agents--a rheumatology perspective |
| Q46309451 | Antiarthritic Activity of Qi-Wu Rheumatism Granule (a Chinese Herbal Compound) on Complete Freund's Adjuvant-Induced Arthritis in Rats |
| Q37169431 | Apoptotic cell infusion treats ongoing collagen-induced arthritis, even in the presence of methotrexate, and is synergic with anti-TNF therapy. |
| Q42639324 | Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis |
| Q38235570 | Atacicept as an investigated therapy for rheumatoid arthritis |
| Q37639837 | Attenuation of Collagen-Induced Arthritis in rat by nicotinic alpha7 receptor partial agonist GTS-21. |
| Q58569029 | B Cell Regulation in Autoimmune Diseases |
| Q38979169 | Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE. |
| Q38425831 | Biologic therapies in systemic lupus erythematosus |
| Q55286510 | CD28 between tolerance and autoimmunity: the side effects of animal models. |
| Q36906622 | CP-25, a novel compound, protects against autoimmune arthritis by modulating immune mediators of inflammation and bone damage. |
| Q35539225 | Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ |
| Q36919720 | Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. |
| Q52932746 | Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. |
| Q38894091 | Control of autoimmune inflammation by celastrol, a natural triterpenoid |
| Q35888963 | Crude triterpenoid saponins from Anemone flaccida (Di Wu) exert anti-arthritic effects on type II collagen-induced arthritis in rats |
| Q46766067 | Cyclophilin D disruption attenuates lipopolysaccharide-induced inflammatory response in primary mouse macrophages |
| Q38673420 | Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases |
| Q41108607 | Decrease of Markers Related to Bone Erosion in Serum of Patients with Musculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy. |
| Q60949975 | Defective T-Cell Apoptosis and T-Regulatory Cell Dysfunction in Rheumatoid Arthritis |
| Q57557905 | Design, synthesis and evaluation of ()-3-(7-(methyl(7-pyrrolo[2,3-]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor |
| Q92732238 | Differential gene expression in articular cartilage between rheumatoid arthritis and endemic Kashin-Beck disease |
| Q38434264 | Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis |
| Q35208102 | Dysregulated serum IL-23 and SIRT1 activity in peripheral blood mononuclear cells of patients with rheumatoid arthritis |
| Q33657543 | Effects of VLA-1 Blockade on Experimental Inflammation in Mice |
| Q41623500 | Effects of leukotriene B4 on interleukin-32, interferon-γ and chemokines in rats with rheumatoid arthritis |
| Q41468717 | Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. |
| Q90052768 | Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies |
| Q88483704 | Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets |
| Q95292554 | Fluvastatin prevents the development of arthritis in env-pX rats via up- regulation of Rho GTPase-activating protein 12 |
| Q47122664 | Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis. |
| Q40702107 | Human Adipose-Derived Mesenchymal Stem Cells Modulate Experimental Autoimmune Arthritis by Modifying Early Adaptive T Cell Responses. |
| Q38987028 | Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways |
| Q90732961 | Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases |
| Q36088239 | Immune Recognition of Citrullinated Proteoglycan Aggrecan Epitopes in Mice with Proteoglycan-Induced Arthritis and in Patients with Rheumatoid Arthritis |
| Q35038322 | Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis |
| Q61449138 | Increased Risk of Thyroid Dysfunction Among Patients With Rheumatoid Arthritis |
| Q52661869 | Inhibition of B-cell apoptosis is mediated through increased expression of Bcl-2 in patients with rheumatoid arthritis. |
| Q37340305 | Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage |
| Q36015739 | Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production |
| Q37000614 | Joint-specific DNA methylation and transcriptome signatures in rheumatoid arthritis identify distinct pathogenic processes |
| Q35825915 | Local but Not Systemic Administration of Uridine Prevents Development of Antigen-Induced Arthritis |
| Q37063297 | Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice |
| Q37697988 | Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. |
| Q38844780 | Macrophage heterogeneity in the context of rheumatoid arthritis. |
| Q26750562 | Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis |
| Q38388828 | Mechanisms and therapeutic potential of inhibiting drug efflux transporters |
| Q52360499 | Modeling Cell-to-Cell Communication Networks Using Response-Time Distributions. |
| Q56891645 | Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases |
| Q91633965 | Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis |
| Q90418789 | Multivariate Comparison of Cytokine Profiles for Normal- and Low-Bone-Density Subjects |
| Q35463538 | MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells |
| Q40538846 | Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β. |
| Q35115477 | Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease |
| Q91276784 | Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis |
| Q52850393 | OMIP-034: Comprehensive immune phenotyping of human peripheral leukocytes by mass cytometry for monitoring immunomodulatory therapies. |
| Q38697262 | Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development |
| Q89576490 | Ontology and Function of Fibroblast-Like and Macrophage-Like Synoviocytes: How Do They Talk to Each Other and Can They Be Targeted for Rheumatoid Arthritis Therapy? |
| Q38434311 | Optimizing treatment in paediatric rheumatology--lessons from oncology |
| Q88489409 | Possible use of miRNAs-146a and -499 expression and their polymorphisms as diagnostic markers for rheumatoid arthritis |
| Q54224169 | Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4+ T-cell development during rheumatoid arthritis. |
| Q47806628 | Protective effects of paeonol on inflammatory response in IL-1β-induced human fibroblast-like synoviocytes and rheumatoid arthritis progression via modulating NF-κB pathway. |
| Q27686770 | Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis |
| Q28262381 | Regulation of tumour necrosis factor signalling: live or let die |
| Q99565517 | Rheumatoid arthritis |
| Q38200701 | Rheumatoid arthritis and the biological clock. |
| Q36673061 | Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis |
| Q46350423 | Role of hydrotherapy in the amelioration of oxidant-antioxidant status in rheumatoid arthritis patients. |
| Q38782633 | Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique |
| Q30638240 | Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine |
| Q36318396 | Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways |
| Q34224001 | Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. |
| Q48136052 | Synovial fibroblast-targeting liposomes encapsulating an NF-κB-blocking peptide ameliorates zymosan-induced synovial inflammation |
| Q38264691 | Targeted delivery systems for biological therapies of inflammatory diseases |
| Q51102102 | Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. |
| Q97541445 | The E3 ubiquitin ligase Itch deficiency promotes antigen-driven B-cell responses in mice |
| Q57492001 | The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis |
| Q60689433 | The Sesquiterpene Lactone, Budlein A, Inhibits Antigen-Induced Arthritis in Mice: Role of NF-κB and Cytokines |
| Q48265755 | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. |
| Q60912321 | The oncoprotein TBX3 is controlling severity in experimental arthritis |
| Q47990642 | Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis. |
| Q60043881 | Therapeutic benefits of Indole-3-Carbinol in adjuvant-induced arthritis and its protective effect against methotrexate induced-hepatic toxicity |
| Q55411306 | Transforming Growth Factor-β and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals. |
| Q28548580 | Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases |
| Q38367194 | Trojan horses and guided missiles: targeted therapies in the war on arthritis. |
| Q92899755 | [89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study |
Search more.